

HYLORIS PHARMACEUTICALS SA

ISIN: BE0974363955 WKN: A2P7Y0 Asset Class: Stock

Company

2024/04/26 17:37:36



Price

11.70

EUR

Difference

-1.27% (-0.15)



Contact Details

HYLORIS PHARMACEUTICALS SA

Tel: +32-4-346-02-07

--

Fax: +

Boulevard Patience et Beaujonc N°3/1

Web: <http://www.hyloris.com>

4000 Liege

E-mail: contact@hyloris.com

Company Profile

Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. It offers commercial-stage products, Sotalol IV for the treatment of atrial fibrillation; and Maxigesic IV, a novel, dual modeof-action non-opioid analgesic for the treatment of post-operative pain. The company was founded by Stijn van Rompay and Thomas Jacobsen in 2012 and is headquartered in Liege, Belgium.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	35,276,000		50,801,000		53,959,000	
Common stock capital		140,000		140,000		129,000
Fixed assets	12,336,000		11,063,000		9,485,000	
Equity capital of a company		38,822,000		55,045,000		48,057,000
Cash and cash equivalents	30,196,000		43,457,000		50,012,000	
Accrued liabilities		-		0		0
Other assets	-		-		-	
Current liabilities		6,937,000		5,772,000		14,978,000
Prepayments and accrued income		-		-		-
Non-current liabilities		1,854,000		1,047,000		409,000
Different income		-		-		-
Other liabilities		0		0		0
Total assets	47,612,000	47,612,000	61,864,000	61,864,000	63,444,000	63,444,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	-	37	-
Equity ratio	81.54%	88.98%	75.75%
Debt-equity ratio	22.64%	12.39%	32.02%

Others

	2023	2022	2021
Tax Expense Rate	0.00%	2.84%	0.78%

HYLORIS PHARMACEUTICALS SA

ISIN: BE0974363955 WKN: A2P7Y0 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	2,814,000	2,951,000	3,096,000
Net income	-15,762,000	-10,770,000	-11,579,000
EBIT	-16,089,000	-10,702,000	-10,927,000
Operating income before taxes	-15,615,000	-10,951,000	-11,478,000
Cash Flow	-12,323,000	-15,031,000	-11,250,000
Net interest income	474,000	-249,000	-551,000
Research and development expenses	14,749,000	10,151,000	5,033,000
Income taxes	0	-311,000	-90,000
Result from investments in subsidiaries, associates and other	-147,000	-130,000	-191,000
Revenues per employee	-	79,757	-

Board of Directors

Stefan Yee	Chairman of Supervisory Board
Carolyn Myers	Member of Supervisory Board
Chris Buyse	Member of Supervisory Board
James Gale	Member of Supervisory Board
Leon van Rompay	Member of Supervisory Board
Marc Foidart	Member of Supervisory Board
Thomas Jacobsen	Member of Supervisory Board

Members of Management Board

Stijn van Rompay	Chairman of Managing Board
Dietmar Aichhorn	Member of Executive Committee
Jean-Luc Vandebroek	Member of Executive Committee
Koenraad van der Elst	Member of Executive Committee
Thomas Jacobsen	Member of Executive Committee